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Between 2006 and 2017, frailty prevalence decreased in HIV-
positive individuals aged 50  years but presented a 3-fold 
increase among those 75 years of age. This dynamic relation-
ship, defined as the frailty compression ratio, represents the net 
result of gero-inducing and gero-protective competing forces, 
described in the cohort.
Keywords. aging; frailty; frailty compression; gero-protector; 
gero-inducer; HIV.
Projections estimate that the number of people aged 60 years 
and older is expected to reach 2 billion worldwide by 2050 [1]. 
Global aging is accompanied by an increased prevalence of age-
related conditions, which tend to accumulate, occur concur-
rently, and interact between themselves [2].
Frailty may replace the metric of chronological age by pro-
viding a more accurate measure of an individual’s overall bio-
logical and functional status [3]. Frailty may also be considered 
as a public health outcome, promoting interventions aimed at 
postponing frailty, thereby reducing the number of years spent 
with disabilities and comorbidities.
At a clinical level, the geriatric construct of “frailty” is the 
net result of competing forces, some acting as gero-protectors 
others as gero-inducers, unbalancing the homeostatic reserves 
against stressors and exposing the individual to a higher risk 
of negative outcomes, including falls, disability, comorbidities, 
cognitive impairment, and death [4].
In the last decade, the management of people living with HIV 
(PLWH) has significantly improved. The “test and treat” para-
digm has reduced the proportion of PLWH experiencing a low 
nadir CD4 and resultant poor immunological recovery. This has 
occurred alongside the availability of less toxic and more effec-
tive antiretrovirals (ARVs). This has allowed the withdrawal of 
toxic nucleoside reverse transcriptase inhibitors (d-drugs) and 
the progressive introduction of integrase inhibitors as the base 
of antiretroviral therapies (ARTs) [5].
The changing demographics in PLWH are evolving in a sim-
ilar manner and represent a paradigm of this global scenario. The 
early introduction of effective and less toxic ART has progres-
sively improved overall survival in PLWH; this may be considered 
a gero-protective phenomenon [6]. Contrarily, the increase in 
the median age (currently about 50 years in high-income coun-
tries), along with other factors, is the main driving force behind 
the increasing prevalence of noncommunicable diseases (NCDs), 
which can be considered a gero-inducing phenomenon [7].
We hypothesized that this evolving clinical scenario could be 
represented over the past 10 years by a change in the frailty prev-
alence, delaying frailty onset to an older age in this population.
We explored the dynamic relationship between chronologic 
age and frailty by assessing the prevalence of being frail at the 
ages of 50 and 75 years in PLWH over the period 2006–2017. To 
operationalize this relationship, we developed a novel metric, 
the frailty compression ratio (FCR).
METHODS
We performed a retrospective evaluation of 3321 PLWH 
on stable ART attending the Modena HIV Metabolic Clinic 
(MHMC; Modena, Italy). This is a tertiary-level referral center 
specifically dedicated to the prevention and treatment of NCDs, 
multimorbidity (defined as the simultaneous presence of more 
than 3 NCDs), and frailty in Italian PLWH.
Frailty was described using the Frailty Index (FI), a tool com-
puting the accumulation of age-related health deficits (ie, clinical 
signs, symptoms, comorbidities, and laboratory abnormalities), 
captured during a standard comprehensive evaluation at the 
MHMC. We used a previously validated FI, based on 37 health 
variables routinely collected at each clinical visit [8].
The FI has been found to predict risk in increments as low as 
0.01, as well as 0.10. For a clinical study, we chose increments 
of 0.10. Recognizing that there would be very few people with 
low FI counts in a clinical sample and that there is poor survival 
at high FI scores, we grouped participants into the following 3 
categories: fit <0.3, frail 0.31–0.39, and frailest >0.40 [9].
In this study, a novel metric, termed the frailty compression 
ratio (FCR), was developed. The FCR was defined as the ratio 
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between the probability of being in the frailest category at age 
of 75 years and the probability of being in the frailest category 
at the age of 50 years. The probability of being frailest as a func-
tion of age was estimated using separate fourth-order poly-
nomial logistic regression (most frail vs fit/frail) for each year 
between 2006 and 2017, based on the population of the MHMC 
in that year. An increase in this ratio represents a shift of the 
frailty prevalence toward an older age. Predictors of FCR were 
explored with linear regression analysis.
RESULTS
Participants were predominantly men (68.1%), with a median 
age (interquartile range [IQR]) of 49 (45–54) years. The median 
time since HIV diagnosis (IQR) was 19.7 (12.8–24.4) years, and 
the median nadir CD4 cell count (IQR) was 200 (86–300) cells/
µL. The HIV viral load was undetectable in 92% of the cohort.
In the whole cohort, 32.5% in 2006 and in 16.4% in 2017 were 
in the frailest category (P < .001), suggesting an overall decrease 
in the frailty prevalence in this cohort.
Supplementary Table 1 describes the main demographic and 
HIV characteristics of the cohort in 2006 and 2017 and at equal 
intervals during this observation period.
From 2006 to 2017, the probability of being frailest at the 
age of 50 years decreased from 41.1% to 36.2% over the period 
of observation, whereas the probability of being frailest at the 
age of 75 years increased from 23.1% to 68.5% during this time 
period. The FCR thus increased from 0.56 to 1.89. Figure 1 
depicts the change in FCR by calendar year.
Predictors of frailty compression were explored with a 
linear regression model. FCR was independently associated 
with proportion of male individuals (beta = 0.71, P < .01), age 
(beta = 0.56, P = .056), nadir CD4+ T-cell count (beta = 0.86, 
P  <  .001), and proportion of PLWH with HIV duration 
>20 years (beta = 0.84, P < .001).
DISCUSSION
In the present analysis, we documented that the frailty prev-
alence over the past decade has decreased in PLWH aged 50, 
whereas it increased in those aged 75. We describe these trends 
in terms of the FCR in PLWH.
The attempt to shift frailty to advanced age through the 
promotion of healthy life styles, effective disease prevention 
strategies, and appropriate therapeutic interventions is the main 
goal of considering aging in the geriatric population in terms of 
health span, rather than life span.
This study introduced an innovative metric that describes 
at a population level a shift in the prevalence of frailty toward 
an older age. This tool has potential use in monitoring public 
health interventions but cannot be considered at the individual 
level, and therefore it cannot be used to monitor aging in as-
sociation with cellular damage, organ pathology, or disease 
progression.
The public health attempt to describe the number of years 
spent with or without disability or comorbidities in advanced 
age was conceptualized several decades ago by the notion of the 
compression of morbidity, which refers to delaying the onset of 
NCDs [10]. In the geriatric setting, it is now assumed that age-
related disease accumulation is unavoidable, but frailty com-
pression may reduce premature disabling conditions.
To our knowledge, the significant shift in delaying frailty 
observed in our HIV cohort is unprecedented and has never 
been previously described, even for other chronic diseases (eg, 
Parkinson’s, rheumatological or cardio-metabolic conditions; 
all of these also share a notable frailty burden).
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Figure 1.  Frailty prevalence at the ages of 50 and 75 years and frailty compression ratio per calendar year.
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In our cohort, predictors of FCR included HIV duration and 
CD4 nadir. This new epidemiological scenario is consistent with 
contemporary HIV care, which is characterized by the early di-
agnosis and treatment of HIV and use of more effective and less 
toxic ARVs [5, 11]. We cannot prove causation between FCR 
and contemporary care. Nevertheless, the association between 
ARV use and HIV demographic changes seems quite evident. 
From this perspective, it might be argued that contemporary 
HIV care acts in a gero-protective manner, and thus ARVs can 
be considered gero-protective agents.
Gero-protectors are drugs capable of slowing down the un-
derlying biologic processes of aging and extending healthy 
life span [1]. To date, more than 200 compounds have been 
implicated as potential gero-protective agents. For example, 
in a clinical trial, investigators reported that everolimus was 
able to boost immune responses when administered in com-
bination with an influenza vaccine in people older than age 
65 years [12].
With the early initiation of modern ART, the vast majority 
of newly diagnosed PLWH avoid the immunological burden of 
low nadir CD4 count and rapidly achieve an undetectable HIV 
viral load after starting ARVs. This immunological benefit may 
counteract any possible ARV-related toxicity and be the main 
driver of the shift in onset of frailty toward an older age.
This hypothesis should be confirmed in further studies. 
Given global aging and the weakness of some traditional clin-
ical paradigms, including CD4 cell count, it is perhaps time to 
add frailty, rather than age or viro-immunological status, as a 
relevant outcome for HIV medicine. Its adoption as an addi-
tional criterion in the evaluation of new ARVs and strategies 
might be clinically useful. It is also important to agree on reli-
able metrics for capturing the gero-protection of interventions 
for both research and clinical settings.
Our data raise a new debate on the ambivalent nature of ARVs. 
A “Dr. Jekyll ARV” may act as a gero-protector, delaying frailty 
to older age. Meanwhile, a “Mr. Hyde ARV” is a gero-inducer, 
associated with age-related diseases (e.g., cardiovascular, bone, 
or renal disease). HIV remains a unique model of aging as a 
paradigm of the competing and opposite forces involved in epi-
demiological transitions due to aging.
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